
Conmed (CNMD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
321.3M
Gross Profit
177.8M
55.33%
Operating Income
16.0M
4.97%
Net Income
6.0M
1.88%
EPS (Diluted)
$0.19
Balance Sheet Metrics
Total Assets
2.3B
Total Liabilities
1.3B
Shareholders Equity
977.6M
Debt to Equity
1.35
Cash Flow Metrics
Operating Cash Flow
49.7M
Free Cash Flow
37.8M
Revenue & Profitability Trend
Conmed Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.3B | 1.2B | 1.0B | 1.0B | 862.5M |
Cost of Goods Sold | 574.0M | 568.5M | 474.2M | 442.6M | 402.2M |
Gross Profit | 733.0M | 676.2M | 571.2M | 568.0M | 460.3M |
Gross Margin % | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% |
Operating Expenses | |||||
Research & Development | 54.4M | 52.6M | 47.2M | 43.6M | 40.5M |
Selling, General & Administrative | 478.3M | 503.0M | 454.0M | 414.8M | 373.8M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 532.7M | 555.6M | 501.2M | 458.3M | 414.3M |
Operating Income | 200.3M | 120.6M | 70.1M | 109.7M | 46.0M |
Operating Margin % | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 37.3M | 39.8M | 28.9M | 35.5M | 44.1M |
Other Non-Operating Income | - | - | -112.0M | -1.1M | -355.0K |
Pre-tax Income | 163.0M | 80.8M | -70.9M | 73.1M | 1.6M |
Income Tax | 30.6M | 16.4M | 9.7M | 10.6M | -7.9M |
Effective Tax Rate % | 18.8% | 20.3% | 0.0% | 14.4% | -493.7% |
Net Income | 132.4M | 64.5M | -80.6M | 62.5M | 9.5M |
Net Margin % | 10.1% | 5.2% | -7.7% | 6.2% | 1.1% |
Key Metrics | |||||
EBITDA | 272.2M | 192.5M | 27.6M | 179.3M | 118.3M |
EPS (Basic) | $4.29 | $2.10 | $-2.68 | $2.14 | $0.33 |
EPS (Diluted) | $4.25 | $2.04 | $-2.68 | $1.94 | $0.32 |
Basic Shares Outstanding | 30846000 | 30668000 | 30040000 | 29162000 | 28581000 |
Diluted Shares Outstanding | 30846000 | 30668000 | 30040000 | 29162000 | 28581000 |
Income Statement Trend
Conmed Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 24.5M | 24.3M | 28.9M | 20.8M | 27.4M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 237.7M | 242.3M | 191.3M | 183.9M | 177.2M |
Inventory | 346.7M | 318.3M | 332.3M | 231.6M | 194.9M |
Other Current Assets | 31.1M | 30.8M | 28.6M | 23.8M | 17.3M |
Total Current Assets | 640.0M | 615.6M | 581.2M | 460.1M | 416.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Goodwill | 2.2B | 2.3B | 2.3B | 1.7B | 1.7B |
Intangible Assets | 617.7M | 649.5M | 681.8M | 471.0M | 501.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 127.4M | 107.3M | 103.5M | 108.5M | 103.6M |
Total Non-Current Assets | 1.7B | 1.7B | 1.7B | 1.3B | 1.3B |
Total Assets | 2.3B | 2.3B | 2.3B | 1.8B | 1.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 102.2M | 88.2M | 73.4M | 58.2M | 53.3M |
Short-term Debt | 715.0K | 708.0K | 69.7M | 12.2M | 18.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 109.8M | 151.7M | 98.7M | 65.7M | 68.3M |
Total Current Liabilities | 278.1M | 310.7M | 296.6M | 196.6M | 190.2M |
Non-Current Liabilities | |||||
Long-term Debt | 905.1M | 973.1M | 985.1M | 672.4M | 735.2M |
Deferred Tax Liabilities | 74.1M | 60.9M | 66.7M | 68.5M | 57.9M |
Other Non-Current Liabilities | 86.3M | 121.0M | 203.7M | 43.0M | 59.3M |
Total Non-Current Liabilities | 1.1B | 1.2B | 1.3B | 783.9M | 852.4M |
Total Liabilities | 1.3B | 1.5B | 1.6B | 980.6M | 1.0B |
Equity | |||||
Common Stock | 313.0K | 313.0K | 313.0K | 313.0K | 313.0K |
Retained Earnings | 560.3M | 452.5M | 412.6M | 496.6M | 457.4M |
Treasury Stock | 15.6M | 15.0M | 22.8M | 54.1M | 67.6M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 962.7M | 834.2M | 745.5M | 785.4M | 709.0M |
Key Metrics | |||||
Total Debt | 905.8M | 973.8M | 1.1B | 684.7M | 753.6M |
Working Capital | 361.9M | 304.9M | 284.7M | 263.5M | 226.5M |
Balance Sheet Composition
Conmed Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 132.4M | 64.5M | -80.6M | 62.5M | 9.5M |
Depreciation & Amortization | 71.9M | 71.9M | 69.5M | 70.7M | 72.6M |
Stock-Based Compensation | 25.6M | 24.3M | 21.7M | 16.3M | 13.1M |
Working Capital Changes | -39.7M | -39.6M | -90.7M | -55.7M | -29.9M |
Operating Cash Flow | 167.0M | 125.3M | 24.5M | 110.9M | 64.5M |
Investing Activities | |||||
Capital Expenditures | -13.1M | -19.0M | -21.8M | -14.9M | -9.8M |
Acquisitions | 0 | 0 | -227.7M | 0 | -3.9M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -13.1M | -20.0M | -249.5M | -14.9M | -13.6M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -24.7M | -24.5M | -24.0M | -23.3M | -22.8M |
Debt Issuance | 751.0M | 692.0M | 1.3B | 379.2M | 199.0M |
Debt Repayment | -823.0M | -780.0M | -898.0M | -460.4M | -225.2M |
Financing Cash Flow | -151.0M | -110.4M | 222.5M | -168.5M | -65.1M |
Free Cash Flow | 153.9M | 106.3M | 11.6M | 96.9M | 51.5M |
Net Change in Cash | 2.9M | -5.1M | -2.5M | -72.5M | -14.2M |
Cash Flow Trend
Conmed Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
13.40
Forward P/E
10.55
Price to Book
1.62
Price to Sales
1.20
PEG Ratio
10.55
Profitability Ratios
Profit Margin
9.02%
Operating Margin
7.27%
Return on Equity
12.96%
Return on Assets
4.14%
Financial Health
Current Ratio
2.26
Debt to Equity
91.26
Beta
1.21
Per Share Data
EPS (TTM)
$3.81
Book Value per Share
$31.61
Revenue per Share
$42.60
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
cnmd | 1.6B | 13.40 | 1.62 | 12.96% | 9.02% | 91.26 |
Abbott Laboratories | 219.8B | 15.85 | 4.50 | 27.98% | 32.43% | 27.09 |
Boston Scientific | 157.5B | 63.38 | 7.09 | 8.42% | 13.55% | 52.16 |
UFP Technologies | 1.8B | 28.51 | 4.96 | 19.36% | 11.59% | 55.05 |
QuidelOrtho | 1.8B | -0.80 | 0.59 | -11.38% | -12.97% | 90.01 |
Alphatec Holdings | 1.6B | -9.63 | -18.58 | 1,144.21% | -25.77% | -6.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.